COMPASS Pathways plc is a mental health care company operating in the UK and the US, focused on developing psilocybin therapy for the treatment of depression and post-traumatic stress disorder. Their product, COMP360, has completed Phase IIb clinical trials and is in Phase II clinical trials. Founded in 2020 and formerly known as COMPASS Rx Limited, the company is headquartered in London, UK.